Why Healthcare Stocks Win When The Market Crashes
How defensive characteristics and mispriced optionality combine during downturns
To read our full disclaimer, click here.
The best asymmetric opportunities don’t appear during bull markets.
They appear when everyone else is panicking.
And in healthcare microcaps, panic creates mispricings.
While tech stocks crater 70%, consumer discretionary collapses, and even “quality” names built on leverage implode, something different happens in healthcare.
The businesses keep functioning.
The science keeps advancing.
The optionality keeps compounding.
The Defense Nobody Understands
Healthcare isn’t defensive because it’s boring.
It’s defensive because demand is non-negotiable.
When GDP contracts 5%, people don’t postpone cancer treatment. Heart disease doesn’t wait for economic recovery. Diabetes doesn’t care about unemployment rates.
This creates baseline demand that simply doesn’t exist in other sectors.
But here’s the part most investors miss: this defensive quality doesn’t prevent healthcare stocks from falling during crashes.
A microcap biotech can drop 60% in a market panic just like everything else.
The difference isn’t what happens to the stock price.
It’s what happens to the playbook.
When Optionality Becomes More Valuable
In most sectors, recessions destroy optionality.
Companies cut R&D. Product launches get delayed. Expansion plans die.
The future gets smaller.
Healthcare works backwards.
A biotech with Phase III data reading out in six months?
The playbook doesn’t change.
The trial still reads out. The data is either positive or negative. The FDA decision still comes.
A diagnostic company awaiting Medicare reimbursement approval?
The playbook doesn’t change.
The regulatory process continues. Coverage gets approved or denied. The timeline stays the same.
A medical device company with a novel technology in clinical evaluation?
The playbook doesn’t change.
The clinical studies complete. Safety and efficacy get demonstrated or they don’t. Commercial launch proceeds on schedule.
The same binary events that drive value creation in bull markets still happen in recessions.
Clinical trial readouts don’t get postponed because GDP is declining.
FDA approval decisions don’t wait for the S&P 500 to recover.
Medicare coverage determinations don’t pause during bear markets.
Patent exclusivity doesn’t disappear.
The optionality remains intact - same timeline, same catalysts, same potential outcomes.
This creates the setup for asymmetric opportunities: panic-driven price crashes on businesses where the fundamental playbook hasn’t changed at all.
The market treats them like everything else during crashes - sell first, ask questions later.
But the science doesn’t care about the stock market.
The Hunt for Asymmetry
Finding these opportunities isn’t about screening for low valuations or following analyst recommendations.
It’s about identifying the 1-2% of healthcare microcaps that combine:
Multiple shots on goal in the pipeline
Fortress balance sheets or adequate runway
Insider-led management with skin in the game
Mission-critical science solving real problems
Narrative dislocation where the market story lags reality
These setups don’t appear every day.
That’s what this newsletter hunts for: the rare healthcare microcaps where optionality, timelines, and fundamentals appear misaligned with market perception.
If that interests you, you can subscribe here:
Thanks for reading,
Nico
Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of Schwar Capital. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.